Artemether-lumefantrine: P. falciparum — Competitive Intelligence Brief

Artemether-lumefantrine: P. falciparum (Artemether-lumefantrine: P. falciparum) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Infectious Disease.

phase 1 Antimalarial Mitochondrial electron transport chain, Heme detoxification pathway Infectious Disease Small molecule

Target snapshot

Artemether-lumefantrine: P. falciparum (Artemether-lumefantrine: P. falciparum) — Centers for Disease Control and Prevention. Artemether is a fast-acting antimalarial that acts by inhibiting the parasite's mitochondrial electron transport chain, while lumefantrine is a slow-acting antimalarial that acts by inhibiting the parasite's heme detoxification pathway.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artemether-lumefantrine: P. falciparum TARGET	Artemether-lumefantrine: P. falciparum	Centers for Disease Control and Prevention	phase 1	Antimalarial	Mitochondrial electron transport chain, Heme detoxification pathway
Coartem	ARTEMETHER		marketed	Antimalarial [EPC]		2009-01-01
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Qualaquin	QUININE	Sun Pharm Industries	marketed	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01
Malarone	PROGUANIL	GSK	marketed	Antimalarial [EPC]		2000-01-01
Halfan	HALOFANTRINE	GSK	marketed	Antimalarial	Potassium voltage-gated channel subfamily H member 2	1992-01-01
Mepron	ATOVAQUONE		marketed	Antimalarial [EPC]	ATP-binding cassette sub-family G member 2	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

1. London School of Hygiene and Tropical Medicine · 6 drugs in this class
2. Sanofi · 3 drugs in this class
3. Epicentre · 2 drugs in this class
4. University of Oxford · 2 drugs in this class
5. · 2 drugs in this class
6. Frantz Viral Therapeutics, LLC · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Institut de Recherche pour le Developpement · 1 drug in this class
9. Centre de Recherche Médicale de Lambaréné · 1 drug in this class
10. GlaxoSmithKline · 1 drug in this class